KSHV transactivator-derived small peptide traps coactivators to attenuate MYC and inhibits leukemia and lymphoma cell growth

Shimoda et al. present evidence that a small functional peptide derived from the KSHV transactivator could be used to target MYC in cancer. The authors find that the peptide attenuates MYC expression, reduces cell proliferation, and selectively kills cancer cells in tissue culture and a xenograft tu...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Michiko Shimoda, Yuanzhi Lyu, Kang-Hsin Wang, Ashish Kumar, Hiroki Miura, Joshua F. Meckler, Ryan R. Davis, Chanikarn Chantarasrivong, Chie Izumiya, Clifford G. Tepper, Ken-ichi Nakajima, Joseph Tuscano, Gustavo Barisone, Yoshihiro Izumiya
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Accès en ligne:https://doaj.org/article/eaec3f23d40d4e7a83a5c5ddca22da0a
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:Shimoda et al. present evidence that a small functional peptide derived from the KSHV transactivator could be used to target MYC in cancer. The authors find that the peptide attenuates MYC expression, reduces cell proliferation, and selectively kills cancer cells in tissue culture and a xenograft tumor mouse model, by blocking recruitment of coactivator complexes (Nuclear receptor coactivator 2, p300, and SWI/SNF proteins) to the MYC promoter.